These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation. Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816 [TBL] [Abstract][Full Text] [Related]
3. Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report. Levis S; Theodore G J Manag Care Pharm; 2012 May; 18(4 Suppl B):S1-15; discussion S13. PubMed ID: 22716221 [TBL] [Abstract][Full Text] [Related]
4. Screening to Prevent Osteoporotic Fractures: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Viswanathan M; Reddy S; Berkman N; Cullen K; Middleton JC; Nicholson WK; Kahwati LC JAMA; 2018 Jun; 319(24):2532-2551. PubMed ID: 29946734 [TBL] [Abstract][Full Text] [Related]
5. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review. Fink HA; MacDonald R; Forte ML; Rosebush CE; Ensrud KE; Schousboe JT; Nelson VA; Ullman K; Butler M; Olson CM; Taylor BC; Brasure M; Wilt TJ Ann Intern Med; 2019 Jul; 171(1):37-50. PubMed ID: 31009947 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians. Ayers C; Kansagara D; Lazur B; Fu R; Kwon A; Harrod C Ann Intern Med; 2023 Feb; 176(2):182-195. PubMed ID: 36592455 [TBL] [Abstract][Full Text] [Related]
7. Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. Murad MH; Drake MT; Mullan RJ; Mauck KF; Stuart LM; Lane MA; Abu Elnour NO; Erwin PJ; Hazem A; Puhan MA; Li T; Montori VM J Clin Endocrinol Metab; 2012 Jun; 97(6):1871-80. PubMed ID: 22466336 [TBL] [Abstract][Full Text] [Related]
8. Management of postmenopausal osteoporosis and the prevention of fractures. Gambacciani M; Levancini M Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322 [TBL] [Abstract][Full Text] [Related]
9. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective. Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131 [TBL] [Abstract][Full Text] [Related]
10. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. MacLean C; Newberry S; Maglione M; McMahon M; Ranganath V; Suttorp M; Mojica W; Timmer M; Alexander A; McNamara M; Desai SB; Zhou A; Chen S; Carter J; Tringale C; Valentine D; Johnsen B; Grossman J Ann Intern Med; 2008 Feb; 148(3):197-213. PubMed ID: 18087050 [TBL] [Abstract][Full Text] [Related]
11. Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians. Qaseem A; Forciea MA; McLean RM; Denberg TD; ; Barry MJ; Cooke M; Fitterman N; Harris RP; Humphrey LL; Kansagara D; McLean RM; Mir TP; Schünemann HJ Ann Intern Med; 2017 Jun; 166(11):818-839. PubMed ID: 28492856 [TBL] [Abstract][Full Text] [Related]
12. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis. Josse R; Khan A; Ngui D; Shapiro M Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819 [TBL] [Abstract][Full Text] [Related]
13. Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: A systematic review and network meta-analysis. Simpson EL; Martyn-St James M; Hamilton J; Wong R; Gittoes N; Selby P; Davis S Bone; 2020 Jan; 130():115081. PubMed ID: 31626995 [TBL] [Abstract][Full Text] [Related]
14. How to manage postmenopausal osteoporosis? Body JJ Acta Clin Belg; 2011; 66(6):443-7. PubMed ID: 22338309 [TBL] [Abstract][Full Text] [Related]
15. Denosumab. Limited efficacy in fracture prevention, too many adverse effects. Prescrire Int; 2011 Jun; 20(117):145-8. PubMed ID: 21678700 [TBL] [Abstract][Full Text] [Related]
16. Benefits and Harms of Osteoporosis Medications in Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis. Wilson LM; Rebholz CM; Jirru E; Liu MC; Zhang A; Gayleard J; Chu Y; Robinson KA Ann Intern Med; 2017 May; 166(9):649-658. PubMed ID: 28395318 [TBL] [Abstract][Full Text] [Related]
17. Understanding and communicating the benefits and risks of denosumab, raloxifene, and teriparatide for the treatment of osteoporosis. Lewiecki EM; Miller PD; Harris ST; Bauer DC; Davison KS; Dian L; Hanley DA; McClung MR; Yuen CK; Kendler DL J Clin Densitom; 2014; 17(4):490-5. PubMed ID: 24206867 [TBL] [Abstract][Full Text] [Related]
18. Patients with prior vertebral or hip fractures treated with teriparatide in the Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) observational study. Beall DP; Feldman RG; Gordon ML; Gruber BL; Lane JM; Valenzuela G; Yim D; Alam J; Krege JH; Krohn K Osteoporos Int; 2016 Mar; 27(3):1191-1198. PubMed ID: 26556737 [TBL] [Abstract][Full Text] [Related]
19. Osteoporosis Treatment Efficacy for Men: A Systematic Review and Meta-Analysis. Nayak S; Greenspan SL J Am Geriatr Soc; 2017 Mar; 65(3):490-495. PubMed ID: 28304090 [TBL] [Abstract][Full Text] [Related]